Although direct-acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection have demonstrated high rates of sustained virologic response, virologic failure may still occur, potentially leading to the emergence of viral resistance, which can decrease the effectiveness of subsequent treatment.
Objective: To estimate annual direct and indirect health care costs in patients with chronic idiopathic urticaria (CIU) managed with conventional therapies.
Introduction: Concerns were raised about a high occurrence of hepatocellular carcinoma (HCC) after successful treatment of chronic hepatitis C (CHC) by direct-acting antivirals (DAAs).
A new analysis of real-world data has shown that switching to Tresiba (insulin degludec) is highly cost-effective and cost-saving for...
Amarin Corporation plc announced a summary of results from a patient-level, cost-effectiveness analysis of icosapent ethyl (Vascepa). This comprehensive analysis...
Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in infants, young children, and older or immunocompromised adults.
Hepatitis C virus (HCV) treatments have dramatically progressed from poorly tolerated, moderately successful interferon-based therapies to highly effective all-oral interferon-free regimens.
This study aims to evaluate the effectiveness, safety and cost of abiraterone acetate (AA) in patients with mCRPC.
The purpose of this study was to estimate the prevalence and cost of illness of asthma in Germany by retrospectively analysing routine health insurance data.
The prospective, two-year cost-effectiveness study of the IN.PACT Admiral drug eluting balloon (DCB), from Medtronic, carried out in conjunction with...